Tumor Registry of Advanced Renal Cell Carcinoma

iOMEDICO AG1,500 enrolled

Overview

The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.

The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mRCC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Renal Cell Carcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy * Start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 Patients: start of first palliative therapy within 4 weeks before enrollment Exclusion Criteria: \-

Locations (1)

iOMEDICO

Freiburg im Breisgau, Germany

Outcomes

Primary Outcomes

Documentation of therapies

Time frame: 9 years, 3 years per patient

Secondary Outcomes

Documentation of response rate and adverse reactions; development of a numeric prognostic score

Time frame: 9 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.